ZLHQ-5f 是一种CDK2和Topo I双重抑制剂，对 CDK2/CycA2 的IC50值为 0.145 μM。ZLHQ-5f 在 S 期阻滞细胞周期，诱导 HCT116 细胞凋亡 (Apoptosis)，具有良好安全性。

ZLHQ-5f is a dual CDK2 and Topo I inhibitor with an IC 50 of 0.145 μM against CDK2/CycA2. ZLHQ-5f arrests the cell cycle in S-phase, triggers apoptosis in HCT116 cells, and has a good safety profile [1].

ZLHQ-5f shows antiproliferative activity with GI 50 values of 0.949 ± 0.113, 0.821 ± 0.240, 1.124 ± 0.362, 1.945 ± 0.278 and 3.349 ± 0.149 μM against A549, HCT116, MCF-7, HepG2 and LO2 cells, respectively [1].

C28H25N5O2

463.53

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years